Multispecific antibodies, including bispecific, can only meet their full potential if they are well tolerated by the human body.
As such, Light Chain Bioscience has taken advantage of the unique features of human antibody light chains and developed an approach to generate bispecific antibodies that retain the full human sequence and architecture of human antibodies. This format, therefore, is ideally suited for therapeutic application, in particular if prolonged administration to patients is required.
Our expertise in bispecific antibodies for CD47 targeting is leading the field in approaches to selectively and safely target the immune checkpoint to the tumor microenvironment.
We welcome the opportunity to discuss with partners enticed by the use of multipsecific antibody approaches for cancer, including T cell retargeting, as well as other approaches outside oncology.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.